Last reviewed · How we verify

bortezomib, rifampicin

Millennium Pharmaceuticals, Inc. · Phase 1 active Small molecule

bortezomib, rifampicin is a Small molecule drug developed by Millennium Pharmaceuticals, Inc.. It is currently in Phase 1 development. Also known as: bortezomib, rifampicin.

At a glance

Generic namebortezomib, rifampicin
Also known asbortezomib, rifampicin
SponsorMillennium Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bortezomib, rifampicin

What is bortezomib, rifampicin?

bortezomib, rifampicin is a Small molecule drug developed by Millennium Pharmaceuticals, Inc..

Who makes bortezomib, rifampicin?

bortezomib, rifampicin is developed by Millennium Pharmaceuticals, Inc. (see full Millennium Pharmaceuticals, Inc. pipeline at /company/millennium-pharmaceuticals-inc).

Is bortezomib, rifampicin also known as anything else?

bortezomib, rifampicin is also known as bortezomib, rifampicin.

What development phase is bortezomib, rifampicin in?

bortezomib, rifampicin is in Phase 1.

Related